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Regarding ‘Early postoperative
serum cystatin C predicts severe
acute kidney injury following
pediatric cardiac surgery’
To the Editor: We read with interest the recent article by
Zappitelli et al.1 We have three remarks to press on.
The classiﬁcation in mild and severe acute kidney injury
(AKI) as described on page 661 does not correspond to the
one by the Acute Kidney Injury Network. In fact, need for
dialysis should be classiﬁed as stage 3. Furthermore, both the
proposed stages include ‘need for dialysis’ as a condition,
which puzzled us a bit.
We are also confused by the use for different variables of
quintiles or tertiles: why not to use only quintiles?
However, the more important fact, it seems to us, is the
problem of whether all the cystatin C values contained
in the 5th or 3rd percentiles are a true expression of a
deranged renal function rather than that of analytical
imprecision. Using the available data on biological varia-
bility2,3 and an estimated laboratory analytical coefﬁcient
of variation of 4.5% (as the authors do not report their
own one), the calculated reference change value4 for
cystatin C is around 25%. This means that in a single indi-
vidual, only a cystatin change 425% between two measure-
ments can detect a signiﬁcant change in his/her renal
function. Hence, the questions are ‘How many patients in
the 5th and 3rd percentiles for predicting AKI fall below
the reference change value?’ and ‘With this limitation, is
early postoperative cystatin C still effective in predicting
severe AKI?’
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The Authors Reply: We thank Gambaro et al.1 for
their letter. Below are the clarifications for the three
questions raised. First, our outcomes were ‘mild’ or stage
1 acute kidney injury (AKI) or worse (including higher
AKI stages and dialysis) and ‘severe’ or stage 2 AKI
or worse (including stage 3 and dialysis). Dialysis
was correctly included in both the AKI definitions to
assure that patients receiving dialysis, but not fulfilling
serum creatinine (SCr) criteria, were categorized as having
AKI.2 Second, they queried our use of quintiles to
evaluate cystatin C (CysC) values (mg/dl) vs. tertiles to
evaluate % CysC change. We would have preferred
quintiles (more granularity) for all analyses but event rates
within quintile groups were very low for stage 2 AKI,
limiting us to analysis of tertiles. Finally, they note the
issue of CysC biological variability. Although contro-
versial,3 CysC may have higher intraindividual variation
than SCr.4 CysC measurement imprecision can contribute
to subject misclassification in given percentile groups;
we measured all samples in a single batch in a CLIA-
approved clinical laboratory, which would reduce mea-
surement variation. We reported our coefficient of
variation for CysC measurement as 1.1% (page 660).2
Importantly, such misclassification and increased vari-
ability would lead to decreased likelihood of finding
an association with the study outcome. In addition,
the third tertile of % CysC change was composed of
patients with 4 to 143% CysC change from baseline
(Table 3).2 The association with AKI should only get
stronger if we eliminated patients in the lower end (o25%
CysC change).
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